UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE MONTH OF JUNE 2022
 
COMMISSION FILE NUMBER 001-40173
 
MeaTech 3D Ltd.
(Translation of registrant’s name into English)
 
MeaTech 3D Ltd.
5 David Fikes St., Rehovot 7632805 Israel
+972 -73-541-2206
 (Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F:

Form 20‑F ☒   Form 40‑F ☐
 
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
 

COMPANY PRESENTATION

MeaTech 3D Ltd. (the “Company”) hereby furnishes as Exhibit 99.1 an updated corporate presentation (the “Company Presentation”), which provides a summary of certain of the Company’s recent material developments and other related projections.
 
The Company Presentation contains certain projections of the Company’s anticipated results of operations, or assumptions or estimates as to future events or outcomes. Those materials are intended to speak only as of the date of this report and should not be construed as representing projections of the Company’s anticipated results of operations, or assumptions or estimates as to future events or outcomes, as of any subsequent date. By furnishing the projections and other information in the presentation materials, the Company is not undertaking, and the Company expressly disclaims, any obligation to furnish updated or revised projections of the Company’s projected results of operations, or assumptions or estimates as to future events or outcomes, to reflect any events or circumstances occurring or existing at any time after the date hereof (irrespective in any such case of whether the projections, assumptions or estimates set forth in the presentation materials, in light of events or circumstances occurring or existing at any time after the date hereof, shall have ceased to have a reasonable basis).
 
This Form 6-K is incorporated by reference into the Company’s registration statements on Form S-8 (File No. 333-255419) and Form F-3 (File No. 333-264110).
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MeaTech 3D Ltd.
 
 
 
 
 
 
By:
 /s/ Arik Kaufman
 
 
 
Name: Arik Kaufman
 
 
 
Title: Chief Executive Officer
 

Date: June 29, 2022
 
 
EXHIBIT INDEX
 
Exhibit
Description of Exhibit
 
 

 
 
 
 

 
 

 

 
Exhibit 99.1



 PIONEERING MEAT 2 . 0 TM   TM   Investor Presentation   june 2022 
 
 This presentation and oral statements made regarding the subject of this presentation contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Such statements include, without limitation, references to the MeaTech 3D Ltd.’s (the “Company’s”) predictions or expectations of future business or financial performance and its goals and objectives for future operations, financial and business trends, performances, strategies or expectations. In some cases, you can identify forward-looking statements by the words “may,” “might,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. You are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this presentation speak only as of the date of this presentation and the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.   This presentation includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the information. Although we are responsible for all of the disclosures contained in this presentation, including such statistical, market and industry data, we have not independently verified any of the data from third-party sources, nor have we ascertained the underlying economic assumptions relied upon therein. In addition, while we believe the market opportunity information included in this presentation is generally reliable and is based on reasonable assumptions, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by us.Other factors that could materially affect actual results or levels of activity, performance or achievement can be found in the Company's Annual Report on Form 20-F for the period ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the "SEC") on March 24, 2022, including under the caption "Risk Factors," and the Company's other current reports filed with the SEC. If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results or levels of activity, performance or achievement may vary significantly from what we projected.   DISCLAIMERS 
 
2
 Our Leadership Team  ARIK KAUFMAN   Co-Founder & CEO   Arik Kaufman has founded various Nasdaq and TASE traded food-tech firms. He is a founding partner of the BlueSoundWaves collective led by Ashton Kutcher, Guy Oseary and Effie Epstein. Mr. Kaufman has extensive experience in food-tech and biotech law, commercial negotiations, M&A transactions, and licensing agreements.    YARON KAISERCo-Founder & Chairman  Yaron Kaiser has founded various Nasdaq and TASE traded deep-tech firms and serves as an executive board member for numerus food-tech companies. He is a founding partner of the BlueSoundWaves collective led by Ashton Kutcher, Guy Oseary and Effie Epstein. Mr. Kaiser has wide experience in commercial and corporate law, IPOs, M&A, and corporate governance.  GUY HEFER  CFO   Guy Hefer has vast international business experience and a successful track record of transaction generation and execution. Mr. Hefer was CFO of a tech-focused holding company and an investment banker at Bank Leumi and Barclays Corporate and Investment Bank in Israel and the UK. Guy holds a BA in accounting and economics from Tel Aviv University.  DAN KOZLOVSKI   CTO   Dan Kozlovski specializes in R&D and product development and is an expert in 3D CAD. Mr. Kozlovski has more than 10 years’ experience working in high-tech companies in the printing market, such as HP-Indigo and Nano Dimension. He holds a BSc degree in mechanical engineering and an executive MBA in management technology, innovation and entrepreneurship. 
 
3
 MeaTech Highlights  2019  Initiated activities  June 2022: $52.4M RAISED, 65+ EMPLOYEES, 15 PATENT APPLICATIONS (one granted)  2022  Reported promising results with muscle stem cell differentiation into muscle fibers that better resemble whole cuts of meat  Expanded into the US   Construction expected to commence on our pilot plant in Belgium   Held first tasting event for MITC anchor investors   MeaTech 3D Ltd.   (NASDAQ: MITC)  Bovine & Porcine meat  MeaTech MT  3D Bio Engineering  Peace of Meat BV.  Avian meat   MeaTech US  US marketing   MeaTech Europe  EU Marketing  100%  2021  Acquired Peace of Meat  Initial listing on Nasdaq and delisted from TASE  Initiated porcine cell R&D  Partnered with Ashton Kutcher-led collective  Breakthrough 3.67 oz (100 gram)bio-printed cultured steak  2020  Listed on the Tel Aviv stock exchange (TASE)   Produced stem cells and differentiated them into bovine muscle and fat cells  Printed thin tissue structure and cultured fat inks  100%  100%  100%(1)  Company Timeline  Group Structure and Main Activities  Notes: 1 94.35% held by MeaTech Europe and 5.65% by MeaTech 3D. 
 
4
 Alternative Protein   Market Overview 
 
 COMPLEXITY  ORGANOLEPTIC PROPERTIES   Plant-based alternative meat   Cultivated hybrid meat1  TODAY  NASCENT   Cultivated whole-cut premium meat  BLEEDING EDGE   EVOLVING ALT-MEAT LANDSCAPE  Thin tissue of premium cultivated meat  Note: 1 We define this category as hybrid food with up to 50% of cultivated meat ingredients.  
 
6
 First stop: COMBINING Both Worlds   CULTURED and PLANT-BASED: HYBRID MEATS 
 
7
 MEATECH’S GO TO MARKET STRATEGY: STARTING WITH HYBRID PRODUCTS   Making strategic acquisitions in the cultivated meat sector, including our acquisition of Belgium-based ‘Peace of Meat’ in Q1 2021.  Focusing on improving the taste, texture and nutritional value of plant-based and cell-based proteins.   We believe adding 10-25% of cultured fat or other cultured biomass to a plant-based protein has the potential to result in meatier aromas, flavors, and mouthfeel.  Planning to begin construction of a pilot plant in 2022 to facilitate engagements with prospective strategic partners. Production at the pilot plant is expected to begin in 2023.  MeaTech’s, Peace of Meat's public tasting of hybrid products. 
 
8
 Printing real meat 
 
9
 Our commitment   To Sustainable Development Goals  We have identified areas where MeaTech has the most potential to contribute to the achievement of the UN Sustainable Development Goals and have aligned our business strategy to promote long-term sustainability.   Similarly, as a United Nations Global Compact corporate participant, we update the UN annually on our progress in implementing the UN’s universal principles on human rights, labor, environment and anti-corruption. 
 
 THE IMPACT OF CULTIVATED MEAT   ENVIRONMENTAL IMPACT*  POTENTIAL ADVANTAGES FOR THE MEAT INDUSTRYTHROUGH THE ALIGNMENT WITH ESG CRITERIA IN A CIRCULAR ECONOMY  Up to 78% less freshwater use  Up to 95% less land use  Up to 93% less air pollution  SOCIAL IMPACT  Controlled, sterile production environment designed to ensure safe, high-quality meat   Strengthening local economies through localized production and distribution  Improving animal welfare with slaughter-free meat production  Source: New studies further the case for cultivated meat over conventional meat in the race to net-zero emissions, Good Food Institute  * Reflects estimated environmental impact as compared against conventional beef harvesting by a third-party policy institute. The study assumed cultivated meat production was powered by renewable sources of energy. 
 
11
 Meatech   Strategy & Business Model 
 
 Our planned Go To Market model  Cultivated meat biomass  B2B  Final product elaboration  Structured cultivated meat products  Unstructured cultivated meat products  Producing cells at scale to make fat and protein biomass for use in end products  Selling MeaTech’s ingredients as B2B products  Using cell-based ingredients for unstructured products (e.g., powders, pastes, stock cubes, meatballs, burgers, sausages, etc.)  3D printing and other scaffolding technologies to produce advanced structured products. (Steaks, carpaccio, pralines etc.)  Selling MeaTech’s final products as B2C or B2B products  CULTIVATED BIOMASS PRODUCTION  FINAL PRODUCT MANUFACTURING  DISTRIBUTION & SALES  B2C / B2B 
 
13
 Company  Value (USD)  Total Funding Amount (USD)  3D Printing  Non-GMO  Cell Lines  Structured meat  Ground Products  Chicken  Beef  Pork  Fish  MeaTech 3D Ltd.  Public  54.3 M  52.4 M  Eat Just- Good Meat  1B  267 M  Upside Food  1B   606 M  Mosa Meat  300-500M  96 M  Blue Nalu  300-500M  84.8 M  Future Meat Technologies  900M  387.8 M  Aleph Farms  300-500M  131.4 M  Meatable  300-500M  173 M  SuperMeat   300-500M  76 M  Source: Public information, news, company estimate.* The companies listed above represent those that management views as our key competitors.  Competitive Landscape* 
 
14
 Technology Overview 
 
 Meet our R&D team leaders  Tal KalksteinSoftware Manager  Timofey Shmal3D Printing Expert  Dr. Nadav NoorTissue Engineering & Bio-Printing Expert  Nelly Komarovsky Gulman Mass Production Manager  Daria PetrovCell Isolation & Characterization Manager  Dr. Yoni Moskovitz Cellular Engineering Manager  Shahar ZukranMechanical Engineer  Moshe ManorElectrical & Software Engineer  Matan LivneFPGA Embedded Developer   Dana Hillel Food Science Expert  Dr. Orit Goldman   VP Biology  Itamar Atzmony  VP Engineering 
 
 HIGH THROUGHPUT 3D TISSUE ENGINEERING  3D PRINTING AND INCUBATION   Scaffold materials  Bio-ink formulations  Software development  Note: These images are computer generated and represent future expectations.  MEATECH’S CORE R&D Technology  MULTI-SPECIES CELL-BASED MANUFACTURING  WITH BIOREACTOR SYSTEMS & PROCESSES  Technologies for using chicken, cow and pig stem cellsto produce muscle tissue and fat tissue fibers 
 
17
 CELL COLLECTION  CELL GROWTH  Upon reaching sufficient cell quantities, stem cells are differentiated into fat and muscle cells.  GROUND PRODUCTS  Cell lines are developed to reliably express certain characteristics.  Stem cells are transferred to bioreactors for exponential growth under ideal conditions.  Unstructured cell-based products (beef, chicken or pork): fat, ground, hybrid or formed.  FAT  MUSCLE  MEATECH’S CELL-BASED PROCESS VISION   PRODUCING CULTURED FAT AND MUSCLE CELLS  CELL DIFFERENTIATION 
 
18
 MEATECH'S CULTURED STEAK VISION   A FLEXIBLE MANUFACTURING PROCESS FOR 3D-PRINTED TISSUE  BIO-INKS  3D BIOPRINTING  INCUBATION  STRUCTURED MEAT  Bio-inks formulated from our cell lines and unique scaffolding materials are loaded into our 3D bioprinter.  Bio-inks are accurately printed and cells are assembled as they would be found in conventional muscle.  Printed product is incubated to mature and form tissue.  Produced in fraction of time required to achieve same cut via conventional means.  FAT  MUSCLE 
 
19
 MEATECH’S IP  15 PATENT APPLICATIONS SUBMITTED, 1 GRANTED, 6 TRADE SECRETS IDENTIFIED AND PRESERVED  Cultivated Edible Meat Fabrication Using Bioprinting  Harvesting Bovine Embryonic Inner Cell Mass  Physical Manipulation of Cultivated Tissue  Bioprinter Printhead Design  Growth Support For Cell Culture  Bovine Umbilical Cord Stem Cells As Feeder Layer  3D Printing High Resolution Support Structures  Muscle Stem-Cell Fusing Process 
 
20
 THANK YOU!  WWW.MEATECH3D.COM  No Animals Were Harmed  in the Making of This Slide deck 
 
 Appendices 
 
 Appendix - Balance Sheet  ($, millions)  31-03-2022  31-12-2021  Current Assets  16.9  22.1   Non-Current Assets  23.2   18.5   Total Assets  40.1   40.7   Current Liabilities  3.9  2.8   Non-Current Liabilities  3.6   0.2   Total Liabilities  7.5   3.0   Total Equity  32.6   37.6   Total Liabilities And Equity  40.1   40.7   SOLID BALANCE SHEET, WITH $15.3M IN CASH, NO BANK DEBT AND STRONG IP R&D ASSETS